Home
About
Overview
Sharing Data
ORCID
Help
History (37)
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
MET as a possible target for non-small-cell lung cancer.
See All 37 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MET as a possible target for non-small-cell lung cancer.
MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
View in:
PubMed
subject areas
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Hepatocyte Growth Factor
Humans
Lung Neoplasms
Mutation
Proto-Oncogene Proteins c-met
authors with profiles
Ravi Salgia